

THC Form 7

MONTHLY PROGRESS REPORT

June 2020

Name of CSE Issuer
Trading Symbol:
Number of Outstanding Listed Securities
Date:

THC BioMed Intl Ltd.

THC

158,376,056 common shares and 55,953,634 reserved for Issuance

July 6, 2020

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On June 4, 2020, the Issuer announced that it shipped its ready-to-drink Cannabis Beverage Shot, THC KISS, to British Columbia's legal adult recreational cannabis market.

The Issuer also announced that it had filled a second order for THC KISS to its Saskatchewan dealer. The Province of Alberta is currently in negotiations with THC BioMed to make THC KISS available to the Alberta legal adult recreational cannabis market.

THC KISS is a brand new Cannabis Beverage Shot that promises to offer a different experience compared to edibles and beverages currently available in the grey or legal cannabis markets. THC KISS aims to be an alternative to smoking cannabis that was developed by the Issuer using proprietary extraction methods invented by the Issuer. Each 30ml bottle of THC KISS contains 10 mg of THC.

On June 10, 2020, the Issuer announced that it had filed for a U.S. trademark for the use of "THC Kiss" in the United State of America. In approximately three months, the application will be examined by the U.S. Patent and Trademark Office and the Issuer will be notified if it does not meet all applicable legal requirements. The Issuer holds the trademark for "THC Kiss" in Canada.

On June 19, 2020, THC announced that its ready-to-drink cannabis beverage shot, THC Kiss, had been launched on the bccannabis store website and sold out within hours.

The Issuer also announced that it had entered into a reseller agreement whereby National Cannabis Distribution ("NCB") will buy and resell cannabis products from the Issuer as one of two exclusive resellers of the Issuer's products in Saskatchewan. The term of the Agreement is one year and will automatically renew unless terminated in accordance with the Agreement.

On June 26, 2020, the Issuer reported its financial results for the nine months ended April 30, 2020.

On June 29, 2020, the Issuer announced that its fulfillment team shipped a second shipment of THC Kiss Cannabis Beverage to British Columbia Liquor Distribution Branch. The fulfillment team also completed their first shipment to their new Saskatchewan distributor, National Cannabis Distribution. The shipment was comprised of dried cannabis and the Issuer's ready-to-drink cannabis beverage shot, "THC Kiss".

THC also announced that they had filed for three Canadian trademarks. The proposed design trademarks are the "THC KISS" logo, "THC Plant Science" with the logo and "THC Kiss THC BioMed Plant Science" with the logo. The logo is the swooping leaf logo used by THC for many years. The application will be reviewed and the Issuer will be notified if there are any objections.

2. Provide a general overview and discussion of the activities of management.

Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

THC KISS is now available in British Columbia to the legal adult recreational cannabis market.

THC KISS is a brand new Cannabis Beverage Shot that promises to offer a different experience to edibles and beverages currently available in the grey or legal cannabis markets.

THC KISS aims to be an alternative to smoking cannabis that was developed by the Issuer using proprietary extraction methods invented by the Issuer

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On June 19, 2020, the Issuer announced that they had entered into a reseller agreement whereby National Cannabis Distribution ("NCB") will buy and resell cannabis products from the Issuer as one of the two exclusive resellers of the Issuer's products in Saskatchewan.

The term of the Agreement is one year and will automatically renew unless terminated in accordance with the Agreement.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

On June 10, 2020, the Issuer announced that it had filed for a U.S. trademark for the use of "THC Kiss" in the United State of America. In approximately three months, the application will be examined by the U.S. Patent and Trademark Office and the Issuer will be notified if it does not meet all applicable legal requirements. The Issuer holds the trademark for "THC Kiss" in Canada.

On June 29, 2020, THC announced that they had filed for three Canadian trademarks. The proposed design trademarks are the "THC KISS" logo, "THC Plant Science" with the logo and "THC Kiss THC BioMed Plant Science" with the logo. The logo is the swooping leaf logo used by THC for many years. The application will be reviewed and the Issuer will be notified if there are any objections.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	50,000	Common shares issued following an exercise of options by four optionees	general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

The outbreak of COVID-19 has significantly increased economic uncertainty. In addition, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions and the adoption of remote working, have impacted our business and operations. COVID-19 is impacting our contractors' ability to provide services to us, including professional services such as accounting and auditing due to social distancing measures.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.

FORM 7 – MONTHLY PROGRESS REPORT

3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **July 6, 2020.**

John Miller

 Name of Director or Senior Officer

“John Miller”

 Signature

President and CEO

 Official Capacity

Issuer Details		
Name of Issuer: THC BioMed Intl Ltd.	For Month End June	Date of Report: YYYYMMDD 2020/07/06
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	